

Supplementary Table 1. Risk of Metabolic Syndrome in Gastric Cancer Survivors with Surgical Treatment Compared with Non-cancer Subjects in Propensity Score-matched Analysis

Variable	Model 1		Model 2	
	OR (95% CI)	p-value	OR (95% CI)	p-value
Age	1.016 (0.994–1.039)	0.164	1.021 (0.995–1.046)	0.111
Male sex	1.543 (0.924–2.575)	0.097	1.715 (0.980–3.002)	0.059
Gastric cancer survivors with total gastrectomy ^a	0.258 (0.032–2.105)	0.206		
Gastric cancer survivors with subtotal gastrectomy ^a	0.403 (0.182–0.888)	0.024		
Methods of anastomosis of gastric cancer survivors with surgical treatment ^a				
Total gastrectomy			0.361 (0.057–2.277)	0.278
Subtotal gastrectomy with Billroth I anastomosis			0.730 (0.287–1.854)	0.508
Subtotal gastrectomy with Billroth II anastomosis			0.145 (0.026–0.800)	0.027
Subtotal gastrectomy with Roux-en-Y anastomosis			0.380 (0.011–12.54)	0.587
Subtotal gastrectomy with Pylorus preserving gastrectomy			1.863 (0.170–20.42)	0.611

^aThese multivariable analyses adjusted for age, sex, smoking and alcohol were performed in Model 1 from cohort A and in Model 2 from cohort B. The reference was non-cancer subjects.

Supplementary Table 2. Risk of Metabolic Dysfunction-associated Fatty Liver Disease with Surgical Treatment Compared with Non-cancer Subjects in Propensity Score-matched Analysis

Variable	Model 1		Model 2	
	OR (95% CI)	p-value	OR (95% CI)	p-value
Age	0.992 (0.971–1.012)	0.427		
Male sex	2.619 (1.627–4.217)	<0.001		
Gastric cancer survivors with total gastrectomy ^a	0.138 (0.017–1.124)	0.064		
Gastric cancer survivors with subtotal gastrectomy ^a	0.435 (0.222–0.851)	0.015		
Methods of anastomosis of gastric cancer survivors with surgical treatment ^a				
Total gastrectomy			0.195 (0.031–1.230)	0.082
Subtotal gastrectomy with Billroth I anastomosis			0.439 (0.172–1.118)	0.084
Subtotal gastrectomy with Billroth II anastomosis			0.405 (0.147–1.114)	0.080
Subtotal gastrectomy with Roux-en-Y anastomosis			0.174 (0.005–5.697)	0.326
Subtotal gastrectomy with Pylorus preserving gastrectomy			3.520 (0.310–39.97)	0.310

^aThese multivariable analyses adjusted for age, sex, smoking and alcohol were performed in Model 1 from cohort A and in Model 2 from cohort B. The reference was non-cancer subjects.